NASDAQ$LUNG

Pulmonx Corporation · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Reported a 39% increase in worldwide revenue and a gross margin of 74.8%.

Pulmonx Corporation reported a 39% increase in worldwide revenue for the fourth quarter of 2021, reaching $13.7 million. The company's gross margin also improved to 74.8%. Despite COVID headwinds, the company expanded its base of U.S. treatment centers and submitted a regulatory filing seeking Zephyr Valve approval in Japan.

  • Worldwide revenue increased by 39% to $13.7 million compared to Q4 2020.
  • Gross margin improved to 74.8% from 72.0% in the same period of 2020.
  • U.S. revenue increased by 49% compared to the fourth quarter of 2020.
  • Submitted regulatory filing seeking Zephyr Valve approval in Japan in December 2021

Headline financials

Total Revenue

$13.7M

Previous: $9.83M+39.5%
EPS (adj)

-$0.35

Previous: -$0.27-29.6%
Capital Expenditures

$1.15M

Previous: $693K+65.7%
Free Cash Flow

-$11.9M

Previous: -$7.96M-49.1%
Net Income

-$13M

Previous: -$9.3M-39.8%
Operating Income

-$12.4M

Previous: -$9.35M-32.2%
Gross Profit

$10.3M

Previous: $7.08M+44.8%
Cash & Equivalents

$148M

Previous: $232M-35.9%
Total Assets

$235M

Previous: $264M-10.8%
Stock-Based Comp

$5.35M

Previous: $2.31M+131.5%

Revenue & EPS history

Pulmonx · Revenue · Quarterly

$13.7M

Q4 2021+39.5%vs Q4 2020
Beat estimate in 6 of 10 quarters(60%)
ActualEstimate

Forward guidance

Pulmonx expects revenue for the full year 2022 to be in the range of $55 million to $60 million. Taking into account the ongoing impact of COVID-19, Pulmonx expects revenue for the first quarter 2022 to be in the range of $9 million to $10 million. The Company expects total operating expenses for the full year 2022 to fall within the range of $100 million to $105 million inclusive of stock-based compensation.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-3.4%

Avg return

Earnings day

-4.1%

Avg return

5 days after

-5.3%

Avg return

30 days after

42%

10 / 24 earnings

Positive

+32.2%

Q4 2024

Best reaction

-64.7%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.5%-6.7%+12.6%
Q4 2025+0.6%-6.1%-28.2%
Q3 2025-18.9%-28.6%+29.1%
Q1 2025-21.9%-28.8%-29.6%
Q4 2024+32.2%+30.7%+17.0%
Q3 2024-7.7%+5.2%-4.7%
Q2 2024-8.1%-15.4%+3.7%
Q1 2024+23.3%+21.9%-4.7%
Q4 2023-17.7%-27.9%-36.1%
Q3 2023+6.9%+20.7%+34.2%
Q2 2023-4.1%-8.0%-26.0%
Q1 2023+1.1%-0.2%-1.5%
Q4 2022+20.8%+26.0%+27.1%
Q3 2022-64.7%-61.1%-52.3%
Q2 2022+9.2%+19.9%+5.7%
Q1 2022+0.6%-23.6%-23.9%
Q4 2021-6.9%-2.5%-12.5%
Q3 2021+7.1%+12.6%-23.7%
Q2 2020-7.6%-10.9%-1.6%
Q2 2021+0.1%+6.0%+3.3%
Q1 2020-5.8%-5.3%+9.9%
Q1 2021-8.7%-9.6%-10.3%
Q4 2020-4.1%-3.4%-20.2%
Q3 2020-4.9%-3.4%+5.6%
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro